Bryan Mehlhaff, MD
Urology · Springfield, ORNPI 1518978204
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $686,953 of the $1,045,573 with a category attached, or 65.7%. It is spread thinly across 36 manufacturers, the largest accounting for just 22.3%. Among urology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,086 payments — averaging $962.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$233K
- Johnson & Johnson$146K
- AstraZeneca$144K
- Astellas Pharma US Inc$77K
- Merck$66K
- SN Holdings, LLC$63K
- plus $316K from 30 others
Across 922 payments — averaging $10,235 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$4M
- Pfizer$1.8M
- Janssen Research & Development, LLC$1.2M
- Novartis$969K
- Merck$523K
- Dendreon Pharmaceuticals LLC$452K
- plus $416K from 6 others
What the payments were for
- Consulting fees$190,67818%
- Speaking & faculty fees$686,95366%
- Travel & lodging$137,93613%
- Food & beverage$29,9033%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 205 | $233,455 |
| Johnson & Johnson(2 entities) | 216 | $145,975 |
| AstraZeneca | 150 | $144,450 |
| Astellas Pharma US Inc | 57 | $76,738 |
| Merck | 37 | $66,233 |
| SN Holdings, LLC | 88 | $62,815 |
| Dendreon Pharmaceuticals LLC | 51 | $57,559 |
| Pfizer | 44 | $51,817 |
| Sumitomo Pharma America, Inc. | 28 | $33,740 |
| Sun Pharmaceutical Industries Inc. | 23 | $33,476 |
| Novartis | 25 | $32,206 |
| Progenics Pharmaceuticals, Inc. | 22 | $21,252 |
| Amgen | 15 | $15,879 |
| Myovant Sciences Inc. | 13 | $13,876 |
| Urogpo LLC | 27 | $13,186 |
| Janssen Global Services, LLC | 13 | $7,653 |
| Clovis Oncology, Inc. | 13 | $7,155 |
| Urogen Pharma, Inc. | 10 | $6,386 |
| Ferring Pharmaceuticals Inc. | 7 | $5,786 |
| Medivation LLC. | 3 | $3,000 |
| Janssen Scientific Affairs, LLC | 7 | $2,292 |
| Astrazeneca UK Limited | 1 | $2,240 |
| Exelixis Inc. | 1 | $1,980 |
| Neotract Inc. | 11 | $1,729 |
| Teleflex LLC | 2 | $1,440 |
| Daiichi Sankyo Inc. | 1 | $1,410 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,030 |
| Telix Pharmaceuticals | 1 | $205 |
| Procept Biorobotics Corporation | 2 | $195 |
| Tolmar, Inc. | 2 | $145 |
| Pharmaand GmbH | 1 | $120 |
| AbbVie | 4 | $77 |
| Valencia Technologies Corporation | 1 | $28 |
| Immunitybio, Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,045,573 in reported general payments places this provider in the 95th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 255 | $3,641,530 |
| NubeqaDarolutamide | 261 | $3,420,044 |
| XtandiEnzalutamide | 221 | $3,042,213 |
| YonsaAbiraterone Acet,submicronized | 99 | $989,155 |
| OrgovyxRelugolix | 302 | $778,314 |
| LynparzaOlaparib | 16 | $264,924 |
| Abiraterone Acetate | 58 | $34,489 |
| Finasteride | 457 | $6,520 |
| Tamsulosin Hcl | 238 | $4,250 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 57 | $1,837 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,395 |
| Prednisone | 130 | $879 |
| Oxybutynin Chloride ErOxybutynin Chloride | 33 | $801 |
| Dutasteride | 15 | $555 |
| Testosterone Cypionate | 13 | $254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $145,975 | $3,641,530255 claims |
| BayerNubeqa | $233,455 | $3,420,044261 claims |
| Astellas Pharma US IncXtandi | $76,738 | $3,042,213221 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $33,740 | $778,314302 claims |
| AstraZenecaLynparza | $144,450 | $264,92416 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,292 | $34,48958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 153 urology providers in Oregon.
Other urology in Springfield
- Kevin KrughoffSpringfield$54K
- David DimarcoSpringfield$7K
- Dawn BodellSpringfield$4K
- Brenton SherwoodSpringfield$3K
- Brady WalkerSpringfield$3K
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
- Kyle GillisClackamas$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.